Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN (carbidopa) tablets from Bristol-Myers Squibb Company.

26 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

Covidien introduces PENNSAID to the U.S. market

Covidien, a leading global provider of healthcare products, has introduced PENNSAID (diclofenac sodium topical solution) 1.5% w/w to the U.S. market. PENNSAID is the only FDA-approved topical non-steroidal anti-inflammatory drug in a vehicle solution containing dimethyl sulfoxide, a known penetrating agent. It is indicated for treatment of the signs and symptoms of osteoarthritis of the knee(s).

26 Apr 2010

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

26 Apr 2010

CAT may improve QOL in pediatric oncology patients undergoing therapy: Researchers

As health care professionals continue placing greater emphasis on the quality of life of childhood cancer patients, researchers have found that creative arts therapy may improve QOL in pediatric oncology patients undergoing therapy.

24 Apr 2010

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.

24 Apr 2010

Drinking lemonade prevents kidney stone formation

We've all heard the expression, "when life gives you lemons, make lemonade." Passing a kidney stone would qualify for one of life's "lemons," but did you know that drinking lemonade has been shown to prevent them?

23 Apr 2010

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Herceptin® (trastuzumab) plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach, including gastroesophageal junction cancer.

23 Apr 2010

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).

23 Apr 2010

Columbia Laboratories' net revenues from US progesterone sales for first-quarter up 36%

Columbia Laboratories, Inc. today announced preliminary results for the quarter ended March 31, 2010.

22 Apr 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.

22 Apr 2010

Merck to market and distribute MBL's Td vaccine in the U.S.

MassBiologics of the University of Massachusetts Medical School and Merck & Co., Inc. announced today that they have entered into an agreement that provides Merck with exclusive rights to market and distribute MBL's tetanus and diphtheria toxoids adsorbed (Td) vaccine in the United States, with the exception of Massachusetts, where MBL will continue distributing the vaccine.

21 Apr 2010

Systems biologists integrate new genetic framework to help predict adverse drug reactions

In a major step toward predicting adverse drug reactions, systems biologists at Mount Sinai School of Medicine in New York City have integrated genetic, cellular and clinical information to find out why certain medicines can trigger fatal heart arrhythmias.

21 Apr 2010

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Abraxis BioScience, Inc., a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers.

21 Apr 2010

BDSI Sciences to purchase $10M of securities in registered direct offering

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, announced that it has entered into a definitive securities purchase agreement with a group of select institutional investors to purchase US$10 million of its securities in a registered direct offering. No placement agent was utilized in connection with the offering.

21 Apr 2010

Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Alexion Pharmaceuticals, Inc. today announced that it has completed enrolling patients in all four previously announced prospective, open-label clinical studies investigating Soliris® (eculizumab) as a potential treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) being conducted in North America and multiple European countries.

21 Apr 2010

Semafore Pharmaceuticals' SF1126 PI3K-mTOR inhibitor demonstrates broad anti-tumor activity in lymphoma

Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.

21 Apr 2010

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.

20 Apr 2010

Homeopathy – Is it a safer and effective alternative?

Studies have shown that nearly 45% Britons rely on Homeopathy, a branch of medicine that has been doubted by many and loved by an equal number.

20 Apr 2010

Nausea News and Research

Further Reading

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

Covidien introduces PENNSAID to the U.S. market

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

CAT may improve QOL in pediatric oncology patients undergoing therapy: Researchers

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Drinking lemonade prevents kidney stone formation

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Columbia Laboratories' net revenues from US progesterone sales for first-quarter up 36%

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

Merck to market and distribute MBL's Td vaccine in the U.S.

Systems biologists integrate new genetic framework to help predict adverse drug reactions

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

BDSI Sciences to purchase $10M of securities in registered direct offering

Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Semafore Pharmaceuticals' SF1126 PI3K-mTOR inhibitor demonstrates broad anti-tumor activity in lymphoma

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Homeopathy – Is it a safer and effective alternative?

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News